Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)

Inclusion Criteria:

* Women with newly diagnosed histologically confirmed FIGO Stage IB-IVA carcinoma of the cervix, including squamous, adenosquamous or adenocarcinoma. Women not suitable for surgery due to comorbidities (medical or other conditions) are also considered eligible.
* Age equal to or greater than 18 years
* Being considered for treatment with curative intent using concurrent chemotherapy and pelvic RT.

Exclusion Criteria:

* ECOG performance status greater than 2.
* Other cervical cancer tumour types (e.g. neuroendocrine, serous).
* Carcinoma of the cervical stump.
* Prior hysterectomy.
* Patients who, at the time of the initial evaluation, have already undergone a whole body PET-CT within the last 6 months.
* Contraindications to 18FDG PET-CT or CT of the abdomen and pelvis.
* Inability to lie supine for imaging with PET-CT.
* Contraindication to radiotherapy (i.e., significant Crohn's disease).
* Contraindication to cisplatin chemotherapy (i.e., non-reversible renal failure).
* Inadequate bone marrow function: ANC less than 1.5 X 10\^9, platelets less than 100 X 10\^9.
* Inadequate renal function: Creatinine greater/equal to 150 micromol/L
* Inadequate hepatic function: Bilirubin greater than 1.5 X ULN and SGOT and Alkaline Phosphatase greater than 3 X ULN.
* History of another invasive malignancy within the previous 5 years with the exception of non-melanoma skin cancer.
* Other medical conditions that may preclude chemo-radiation therapy.
* Known pregnancy or lactating.
* Inability to complete study or required follow-up.